SUMO modification of Huntingtin and Huntington's disease pathology

被引:532
|
作者
Steffan, JS
Agrawal, N
Pallos, J
Rockabrand, E
Trotman, LC
Slepko, N
Illes, K
Lukacsovich, T
Zhu, YZ
Cattaneo, E
Pandolfi, PP
Thompson, LM
Marsh, JL
机构
[1] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA
[2] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA
[3] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA
[5] Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol Sci, I-20133 Milan, Italy
[6] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA
关键词
D O I
10.1126/science.1092194
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Huntington's disease (HD) is characterized by the accumulation of a pathogenic protein, Huntingtin (Htt), that contains an abnormal polyglutamine expansion. Here, we report that a pathogenic fragment of Htt (Httex1p) can be modified either by small ubiquitin-like modifier (SUMO)-1 or by ubiquitin on identical lysine residues. In cultured cells, SUMOylation stabilizes Httex1p, reduces its ability to form aggregates, and promotes its capacity to repress transcription. In a Drosophila model of HD, SUMOylation of Httex1p exacerbates neurodegeneration, whereas ubiquitination of Httex1p abrogates neurodegeneration. Lysine mutations that prevent both SUMOylation and ubiquitination of Httex1p reduce HD pathology, indicating that the contribution of SUMOylation to HD pathology extends beyond preventing Htt ubiquitination and degradation.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 50 条
  • [1] Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease
    Tabrizi, Sarah J.
    Ghosh, Rhia
    Leavitt, Blair R.
    NEURON, 2019, 101 (05) : 801 - 819
  • [2] SUMO has big role in Huntington's pathology
    Butcher, J
    LANCET NEUROLOGY, 2004, 3 (05): : 262 - 262
  • [3] Huntingtin aggregation and toxicity in Huntington's disease
    Bates, G
    LANCET, 2003, 361 (9369): : 1642 - 1644
  • [4] Normal huntingtin function in Huntington's disease
    Cattaneo, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 13 - 13
  • [5] HUNTINGTON'S DISEASE Flipping a switch on huntingtin
    Greiner, Erin R.
    Yang, X. William
    NATURE CHEMICAL BIOLOGY, 2011, 7 (07) : 412 - 415
  • [6] Nucleocytoplasmic transport of huntingtin and Huntington's disease
    Truant, R
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 157 - 164
  • [7] The role of the interaction of Huntingtin with p53 and GAPDH in the pathology of Huntington's disease.
    Agrawal, N
    Fujimoro, M
    Igarashi, S
    Hwang, PH
    Taya, T
    Takahashi, M
    Ferris, CD
    Luo, X
    Fang, M
    Sutcliffe, S
    Hayward, SD
    Ross, CA
    Snyder, SH
    Sawa, A
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 54 - 54
  • [8] SUMO-modifying Huntington's disease
    Soares, Ericks S.
    Prediger, Rui D.
    Brocardo, Patricia S.
    Cimarosti, Helena, I
    IBRO NEUROSCIENCE REPORTS, 2022, 12 : 203 - 209
  • [9] Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease (vol 101, pg 801, 2019)
    Tabrizi, Sarah J.
    Ghosh, Rhia
    Leavitt, Blair R.
    NEURON, 2019, 102 (04) : 899 - 899
  • [10] Huntingtin-lowering strategies for Huntington's disease
    Barker, Roger A.
    Fujimaki, Motoki
    Rogers, Priya
    Rubinsztein, David C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1125 - 1132